HIM disease progression and fertility in Dar es Salaam, Tanzania

被引:21
作者
Sedgh, G
Larsen, U
Spiegelman, D
Msamanga, G
Fawzi, WW
机构
[1] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA
[2] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA
[3] Harvard Univ, Sch Publ Hlth, Dept Populat & Int Hlth, Boston, MA 02115 USA
[4] Muhimbili Univ, Coll Hlth Sci, Dept Community Hlth, Dar Es Salaam, Tanzania
关键词
HIV; clinical stage; pregnancy; live births; Africa women;
D O I
10.1097/01.qai.0000148529.58963.83
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives: To examine the association of HIV-1 disease progression with pregnancy and live birth incidence in a cohort of HIV-1-positive women in Dar es Salaam, Tanzania, and to identify other determinants of fertility in this population. Design and Methods: Clinic-based prospective cohort study of HIV-1-infected women followed for LIP to 6 years and Cox proportional hazards models. Results: The multivariate pregnancy rate ratio (RR) comparing women at clinical stage II with women at stage I was 0.56 (95% confidence interval [CI]: 0.39, 0.82), and the pregnancy RR for women at stage III or IV compared with women at stage I was 0.24 (95% Cl: 0.16, 0.36), controlling for independent predictors of pregnancy incidence. Pregnancy rates were lower among older women, unmarried women, women who had revealed their HIV status to someone, and women who had living children from their most recent pregnancy. The association of HIV-1 clinical progression with a decline in pregnancy incidence was not explained by weight loss, menstrual dysfunction, or nutritional status. Conclusion: Pregnancy and live birth rates decline dramatically with progression of HIV-1 disease. This decline is not explained by observed social, behavioral, or biologic factors.
引用
收藏
页码:439 / 445
页数:7
相关论文
共 22 条
[1]  
BARBIERI M, 2000, POP ASS AM 2000 ANN
[2]  
CARPENTER LM, 1997, HLTH TRANSITION REV, V7, P126
[3]   Menstrual function in human immunodeficiency virus-infected women without acquired immunodeficiency syndrome [J].
Chirgwin, KD ;
Feldman, J ;
MuneyyirciDelale, O ;
Landesman, S ;
Minkoff, H .
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1996, 12 (05) :489-494
[4]   Pregnancy rates among women infected with human immunodeficiency virus [J].
Chu, SY ;
Hanson, DL ;
Jones, JL ;
Stetler, H ;
Sorvillo, F ;
Buskin, SE ;
Schulte, J ;
McNaghten, AD ;
Rietmeijer, CA ;
Troxler, S ;
Reynolds, K ;
Coronado, V ;
Martinez, S .
OBSTETRICS AND GYNECOLOGY, 1996, 87 (02) :195-198
[5]  
DESGREESDU LA, 1999, AIDS, V13, P517
[6]  
DUDESGREES L, 1998, INT J STD AIDS, V9, P452
[7]   Characteristics of menstruation in women infected with human immunodeficiency virus [J].
Ellerbrock, TV ;
Wright, TC ;
Bush, TJ ;
Dole, P ;
Brudney, K ;
Chiasson, MA .
OBSTETRICS AND GYNECOLOGY, 1996, 87 (06) :1030-1034
[8]   WEIGHT-LOSS AND MENSTRUAL-CYCLE - CLINICAL AND ENDOCRINOLOGIC EVALUATION [J].
FALSETTI, L ;
PASINETTI, E ;
MAZZANI, MD ;
GASTALDI, A .
GYNECOLOGICAL ENDOCRINOLOGY, 1992, 6 (01) :49-56
[9]   Rationale and design of the Tanzania vitamin and HIV infection trial [J].
Fawzi, WW ;
Msamanga, GI ;
Spiegelman, D ;
Urassa, EJN ;
Hunter, DJ .
CONTROLLED CLINICAL TRIALS, 1999, 20 (01) :75-90
[10]  
FAWZI WW, 1993, AIDS, V7, P711